KRAS and neoplasm: These tumor samples were previously prepared in our recent study of the KRAS–ILK signaling loop, in which daily oral administration of T315 at 50 mg/kg inhibited AsPC-1 xenograft tumor growth by 51% (described in the Supplementary Figure S2 of cited reference;32http://www.nature.com/onc/journal/v35/n30/extref/onc2015458x1.pdf).